Skip to main content

Table 4 Withdrawals and adverse events

From: Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data

      Number of    Percent with   
Outcome Comparator    Trials    Patients Ferric
carboxymaltose
   Control RB or RR
95% CI
NNTp
95% CI
Withdrawals        
All cause All    10    3835    6.4    7.5    0.8 (0.6 to 0.9)    93 (37 to 180)
  Oral iron    6    1898    8.1    9.3    0.8 (0.6 to 1.03)    not calculated
Adverse event All    8    3319    1.0    1.6    0.6 (0.3 to 1.02)    not calculated
  Oral iron    6    1898    1.5    1.9    0.7 (0.3 to 1.4)    not calculated
Lack of efficacy All    7    2967    0.6    0.8    0.8 (0.4 to 1.7)    not calculated
  Oral iron    5    1546    1.1    1.2    0.8 (0.4 to 1.9)    not calculated
Adverse events NNH
95% CI
At least 1 AE All    8    2951    41    38    1.1 (1.0 to 1.2)    not calculated
  Oral iron    5    1539    48    53    1.0 (0.9 to 1.1)    not calculated
Death All    10    3762    0.53    0.3    1.3 (0.5 to 3.4)    not calculated
  Oral iron    6    1891    0.38    0.0    1.7 (0.4 to 6.6)    not calculated
Serious AE All    8    3303    2.5    2.3    1.0 (0.6 to 1.5)    not calculated
  Oral iron    6    1891    3.1    2.3    1.3 (0.7 to 2.2)    not calculated
Hypotension All    6    2694    1.5    1.0    1.5 (0.8 to 2.7)    not calculated
  Oral iron    4    1339    1.3    0.0    4.7 (1.1 to 21)    79 (44 to 390)